Mundipharma to Develop Sosei’s Fentanyl Pain Spray
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 74 (Table of Contents)
Published: 6 Aug-2006
DOI: 10.3833/pdr.v2006.i74.471 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Mundipharma International Holdings (MIH) entered into an alliance to develop and commercialize AD-923, Sosei’s novel sublingual fentanyl spray for cancer breakthrough pain...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS